Improved Outcome for ALL by Prolonging Therapy for IKZF1 Deletion and Decreasing Therapy for Other Risk Groups.
Rob PietersHester de Groot-KrusemanMarta FioccoFemke VerwerMerian Van OverveldEdwin SonneveldVincent H J van der VeldenH Berna BeverlooMarc BieringsNatasja DorsValerie de HaasPeter M HoogerbruggeInge M Van der SluisWim TissingMargreet A VeeningJudith M BoerMonique Den BoerPublished in: Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2023)
, DS, and PPR ALL. It has to be noted that these results were obtained in a nonrandomized study using a historical control group.
Keyphrases